ES2878078T3 - Inhibidores de GSK-3 - Google Patents

Inhibidores de GSK-3 Download PDF

Info

Publication number
ES2878078T3
ES2878078T3 ES17812188T ES17812188T ES2878078T3 ES 2878078 T3 ES2878078 T3 ES 2878078T3 ES 17812188 T ES17812188 T ES 17812188T ES 17812188 T ES17812188 T ES 17812188T ES 2878078 T3 ES2878078 T3 ES 2878078T3
Authority
ES
Spain
Prior art keywords
carboxamide
yield
esi
pyrimidine
calc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17812188T
Other languages
English (en)
Spanish (es)
Inventor
Richard A Hartz
Vijay T Ahuja
Guanglin Luo
Ling Chen
Prasanna Sivaprakasam
Gene M Dubowchik
Swanee E Jacutin-Porte
John E Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2878078T3 publication Critical patent/ES2878078T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES17812188T 2016-11-28 2017-11-27 Inhibidores de GSK-3 Active ES2878078T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662426631P 2016-11-28 2016-11-28
PCT/US2017/063231 WO2018098412A1 (en) 2016-11-28 2017-11-27 Gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
ES2878078T3 true ES2878078T3 (es) 2021-11-18

Family

ID=60655130

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17812188T Active ES2878078T3 (es) 2016-11-28 2017-11-27 Inhibidores de GSK-3

Country Status (8)

Country Link
US (1) US10752609B2 (cg-RX-API-DMAC10.html)
EP (1) EP3544613B1 (cg-RX-API-DMAC10.html)
JP (1) JP7114591B2 (cg-RX-API-DMAC10.html)
KR (1) KR102575990B1 (cg-RX-API-DMAC10.html)
CN (1) CN110545817B (cg-RX-API-DMAC10.html)
ES (1) ES2878078T3 (cg-RX-API-DMAC10.html)
MA (1) MA46889A (cg-RX-API-DMAC10.html)
WO (1) WO2018098412A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110198934B (zh) * 2016-11-28 2022-07-22 百时美施贵宝公司 作为gsk-3抑制剂的嘧啶甲酰胺
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
AU2019404576B2 (en) * 2018-12-20 2025-07-17 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
AU2020325115B2 (en) 2019-08-02 2026-03-12 Amgen Inc. Pyridine derivatives as KIF18A inhibitors
JP7699100B2 (ja) 2019-08-02 2025-06-26 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
CN116178281B (zh) * 2023-04-27 2023-07-21 中国药科大学 一种双功能免疫抑制剂及其制备方法和应用
CN121666382A (zh) * 2023-05-10 2026-03-13 缆图药品公司 GSK3α抑制剂和其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
BRPI0814441A2 (pt) * 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
WO2012024179A1 (en) * 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Substituted amide derivatives as dgat-1 inhibitors
JP2017500287A (ja) * 2013-11-06 2017-01-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体
AU2014347027A1 (en) 2013-11-06 2016-06-23 Bristol-Myers Squibb Company GSK -3 inhibitors
WO2016144792A1 (en) * 2015-03-06 2016-09-15 Alpharmagen, Llc Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
CN110198934B (zh) * 2016-11-28 2022-07-22 百时美施贵宝公司 作为gsk-3抑制剂的嘧啶甲酰胺

Also Published As

Publication number Publication date
MA46889A (fr) 2019-10-02
US20190315714A1 (en) 2019-10-17
US10752609B2 (en) 2020-08-25
KR20190085114A (ko) 2019-07-17
JP7114591B2 (ja) 2022-08-08
JP2019535788A (ja) 2019-12-12
KR102575990B1 (ko) 2023-09-08
EP3544613A1 (en) 2019-10-02
CN110545817A (zh) 2019-12-06
EP3544613B1 (en) 2021-06-09
CN110545817B (zh) 2022-11-15
WO2018098412A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
KR102575990B1 (ko) Gsk-3 억제제
CA2863515C (en) Pyridone derivatives
ES2536479T3 (es) Derivados de la piridina y la pirazina como moduladores de la proteína quinasa
AU2015313782B2 (en) Compounds and compositions as RAF kinase inhibitors
KR102339227B1 (ko) Gsk-3 억제제
BR112020026748A2 (pt) Inibidores de quinases dependentes de ciclina
RU2692479C2 (ru) (5,6-дигидро)пиримидо[4,5-е]индолизины
KR102292433B1 (ko) Gsk-3 억제제로서 유용한 치환된 피리딘 유도체
EA039808B1 (ru) Аминотриазолопиридины в качестве ингибиторов киназ
EP3694330B1 (en) Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
IL296265A (en) Fused pyrimidine compounds as kcc2 modulators
CN104837829A (zh) 抑制剂化合物
AU2017208555A1 (en) New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
KR20240047371A (ko) Cd38 조절제 및 이의 사용 방법
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CA2630360A1 (en) Substituted bicyclic pyrimidone derivatives
ES2896938T3 (es) Inhibidores de GSK-3